Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and disease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
—
Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and disease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
—
Daily adjusted close
Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and disease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.